Diacerein (cas 13739-02-1) protects against glycerol-induced acute kidney injury: Modulating oxidative stress, inflammation, apoptosis and necroptosis
-
Add time:09/10/2019 Source:sciencedirect.com
Necroptosis is suggested to have an important role in the pathogenesis of rhabdomyolysis induced acute kidney injury (AKI). In this study, the renoprotective effect of Diacerein (cas 13739-02-1) on glycerol-induced AKI was investigated. Twenty four male albino rats were included in this study and divided into four groups: (group I) saline control group, (group II) glycerol-treated group, (groups III&IV) diacerein + glycerol -treated groups (25 and 50 mg/kg/day) respectively. Renal malondialdehyde (MDA) level in addition to catalase and heme oxygenase (HO) activities were estimated. Comet assay and histopathological changes were evaluated. The levels of pro-apoptotic Bcl-2-associated X (Bax) protein, tumor necrosis factor alpha (TNF-α) and receptor-interacting serine/threonine-protein kinases 3 (RIPK3) were measured by ELISA. RIPK3 and mixed lineage kinase domain-like pseudokinase (MLKL) mRNA expression were assessed by real time PCR. Glycerol treatment caused significant renal histological abnormalities and functional impairment (increased urea and creatinine). Increased levels of renal MDA with concomitant decrease in renal catalase activity and significant DNA damage in comet assay were observed. High expression of RIPK3 and MLKL in the glycerol-treated group with marked elevation of Bax, TNF-α and RIPK3 levels and HO-1 activity were also documented. Diacerein treatment dependently attenuated glycerol induced structural and functional changes in kidney and significantly elicit reduction of renal tissue oxidative damage whereas it decreased renal expression of RIPK3 and MLKL, and decreased Bax, TNF-α and RIPK3 levels and HO-1 activity.
We also recommend Trading Suppliers and Manufacturers of Diacerein (cas 13739-02-1). Pls Click Website Link as below: cas 13739-02-1 suppliers
Prev:Novel spectrophotometric methods for the determination of Leflunomide and Diacerein (cas 13739-02-1) in binary mixtures
Next:Mechanical exposure and Diacerein (cas 13739-02-1) treatment modulates integrin-FAK-MAPKs mechanotransduction in human osteoarthritis chondrocytes) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Pharmacological treatment with Diacerein (cas 13739-02-1) combined with mechanical stimulation affects the expression of growth factors in human chondrocytes09/29/2019
- Formulation and optimization of niosomes for topical Diacerein (cas 13739-02-1) delivery using 3-factor, 3-level Box-Behnken design for the management of psoriasis09/28/2019
- Original articleDiacerein (cas 13739-02-1) orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial10/01/2019
- Original articleDiacerein (cas 13739-02-1) alleviates kidney injury through attenuating inflammation and oxidative stress in obese insulin-resistant rats09/27/2019
- Original ArticleValidated determination of Diacerein (cas 13739-02-1) and its active metabolite, rhein, by stability indicating constant pattern method as a novel manipulation of zero order spectra09/26/2019
- Diacerein (cas 13739-02-1) inhibits Estradiol-benzoate induced cervical hyperkeratosis in female rats09/25/2019
- Mechanical exposure and Diacerein (cas 13739-02-1) treatment modulates integrin-FAK-MAPKs mechanotransduction in human osteoarthritis chondrocytes09/24/2019
- Novel spectrophotometric methods for the determination of Leflunomide and Diacerein (cas 13739-02-1) in binary mixtures09/09/2019
- Original articlePharmacokinetics and bioequivalence study of rhein as the main metabolite of Diacerein (cas 13739-02-1)09/08/2019